Evidence map›Paper›PMID 36439133›Full record

ArticleFrontiers in immunology2022

Role of FK506-sensitive signals in asthmatic lung inflammation.

Chihiro Tomiaki, Kosuke Miyauchi, Sewon Ki, Yoshie Suzuki, Narumi Suzuki, Hiroshi Morimoto, Yohei Mukoyama, Masato Kubo

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Chihiro TomiakiLaboratory for Cytokine Regulation, Research Center for Integrative Medical Sciences (IMS), RIKEN Yokohama Institute, Yokohama, Kanagawa, Japan.
Kosuke MiyauchiLaboratory for Cytokine Regulation, Research Center for Integrative Medical Sciences (IMS), RIKEN Yokohama Institute, Yokohama, Kanagawa, Japan.
Sewon KiLaboratory for Cytokine Regulation, Research Center for Integrative Medical Sciences (IMS), RIKEN Yokohama Institute, Yokohama, Kanagawa, Japan.
Yoshie SuzukiLaboratory for Cytokine Regulation, Research Center for Integrative Medical Sciences (IMS), RIKEN Yokohama Institute, Yokohama, Kanagawa, Japan.
Narumi SuzukiLaboratory for Cytokine Regulation, Research Center for Integrative Medical Sciences (IMS), RIKEN Yokohama Institute, Yokohama, Kanagawa, Japan.
Hiroshi MorimotoMedical Affairs Department, Maruho Co., Ltd., Osaka, Japan.
Yohei MukoyamaGlobal Business Development Department, Maruho Co., Ltd., Kyoto, Japan.
Masato KuboLaboratory for Cytokine Regulation, Research Center for Integrative Medical Sciences (IMS), RIKEN Yokohama Institute, Yokohama, Kanagawa, Japan.
RIKEN Center for Integrative Medical Sciences · JPMaruho (Japan) · JPTokyo University of Science · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Asthma is airway inflammatory diseases caused by the activation of group 2 innate lymphoid cells (ILC2s) and type 2 helper T (T

Indexed as

AsthmaCysteine ProteasesEosinophiliaPneumoniaAllergensAnimalsImmunity, InnateInflammationInterleukin-1 Receptor-Like 1 ProteinLymphocytesMiceTacrolimusAllergensCysteine ProteasesInterleukin-1 Receptor-Like 1 ProteinTacrolimusasthmacytokinesIL-13innate lymphocyte cells (ILCs)Th2 airway inflammation

Identifiers

PMID36439133
PMCPMC9683035
OpenAlexW4308719995

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.